Intestinal Immunity and Gut Microbiota in Atherogenesis

Area of Science:

• Immunology
• Microbiology
• Cardiology

Background:

• Atherosclerosis is a chronic inflammatory disease linked to cardiovascular diseases (CVD).
• The gut microbiota's role in cardio-metabolic diseases and intestinal immunity is gaining attention.
• Gut microbiota can exacerbate CVD by producing the pro-atherogenic compound trimethylamine-N-oxide (TMAO).

Purpose of the Study:

• To review the evidence linking gut microbiota to cardio-metabolic diseases.
• To explore the intestine as a potential therapeutic target for preventing atherosclerotic CVD.
• To consider gut microbiota as a diagnostic and therapeutic tool for CVD.

Main Methods:

• Review of existing literature on gut microbiota, immunity, metabolism, and CVD.
• Analysis of previous findings on oral anti-CD3 antibodies and vitamin D3 in reducing atherosclerosis.
• Examination of studies investigating gut microbiota composition in coronary artery disease (CAD) patients.

Main Results:

• Oral administration of anti-CD3 antibodies and vitamin D3 reduced atherosclerosis in mice.
• Gut microbiota is associated with intestinal immunity and metabolism, influencing CVD.
• CAD patients showed increased Lactobacillales and decreased Bacteroidetes compared to controls.

Conclusions:

• The intestine presents a novel therapeutic target for preventing atherosclerotic CVD.
• Gut microbiota composition is significantly altered in CAD patients.
• Gut microbiota holds potential as a future diagnostic and therapeutic tool for CVD management.